A. Kim

Hepatology · Science · 2010–2023

A researcher in the Science corpus: 5 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom A. Kim trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Aasld Idsa Hcv Guidance Panel

Papers from A. Kim's perspective

Ordered by how strongly the researchers A. Kim trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Sofosbuvir for previously untreated chronic hepatitis C infection. (New England Journal of Medicine)
  2. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. (New England Journal of Medicine)
  3. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive… (The Lancet)
  4. Management of hepatocellular carcinoma: An update (Hepatology)
  5. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 (Annals of Internal Medicine)
  6. Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma (Annals of Internal Medicine)
  7. Sampling variability of liver fibrosis in chronic hepatitis C (Hepatology)
  8. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. (Journal of the American Medical Association (JAMA))
  9. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. (MMWR Recommendations and Reports)
  10. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. (New England Journal of Medicine)

Their papers